4//SEC Filing
OrbiMed Israel GP Ltd. 4
Accession 0000947871-21-000520
CIK 0001551986other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 6:34 PM ET
Size
15.4 KB
Accession
0000947871-21-000520
Insider Transaction Report
Form 4
OrbiMed Israel GP Ltd.
Director10% Owner
Transactions
- Exercise of In-Money
Common Stock
2021-05-11$0.70/sh+12,500$8,750→ 25,729,255 total(indirect: See Footnotes) - Exercise of In-Money
Stock Option (right to buy)
2021-05-11+12,500→ 37,500 total(indirect: See Footnotes)Exercise: $0.70Exp: 2030-04-30→ Common Stock (12,500 underlying) - Exercise of In-Money
Common Stock
2021-05-11$0.62/sh+19,444$12,086→ 25,748,699 total(indirect: See Footnotes (1)(2) - Exercise of In-Money
Stock Option (right to buy)
2021-05-11+19,444→ 80,556 total(indirect: See Footnotes)Exercise: $0.62Exp: 2030-07-06→ Common Stock (19,444 underlying)
OrbiMed Israel BioFund GP Limited Partnership
Director10% Owner
Transactions
- Exercise of In-Money
Common Stock
2021-05-11$0.70/sh+12,500$8,750→ 25,729,255 total(indirect: See Footnotes) - Exercise of In-Money
Common Stock
2021-05-11$0.62/sh+19,444$12,086→ 25,748,699 total(indirect: See Footnotes (1)(2) - Exercise of In-Money
Stock Option (right to buy)
2021-05-11+12,500→ 37,500 total(indirect: See Footnotes)Exercise: $0.70Exp: 2030-04-30→ Common Stock (12,500 underlying) - Exercise of In-Money
Stock Option (right to buy)
2021-05-11+19,444→ 80,556 total(indirect: See Footnotes)Exercise: $0.62Exp: 2030-07-06→ Common Stock (19,444 underlying)
Footnotes (4)
- [F1]These shares of the Issuer's common stock are held of record by Nissim Darvish ("Darvish"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OrbiMed Israel Partners Limited Partnership ("OIP"), and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
- [F2]This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F3]This option was granted to Darvish on April 30, 2020 and vests in 36 monthly installments beginning April 30, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
- [F4]This option was granted to Darvish on July 6, 2020 and vests in 36 monthly installments beginning July 6, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
Documents
Issuer
9 METERS BIOPHARMA, INC.
CIK 0001551986
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001569590
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 6:34 PM ET
- Size
- 15.4 KB